Crossmark

¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares?

Crossref DOI link: https://doi.org/10.1016/j.arteri.2020.08.001

Published Print: 2021-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Vargas Delgado, Ariana P.

Requena Ibañez, Juan Antonio

Santos-Gallego, Carlos G.

Badimon, Juan Jose
License Information

Text and Data Mining valid from 2021-01-01
More Information

This article is maintained by: Elsevier

Article Title: ¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares?

Journal Title: Clínica e Investigación en Arteriosclerosis

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.arteri.2020.08.001

Content Type: article

Copyright: © 2020 Sociedad Española de Arteriosclerosis. Published by Elsevier España, S.L.U. All rights reserved.